US4464467A
(en)
*
|
1982-07-26 |
1984-08-07 |
Bristol-Myers Company |
Antitumor antibiotics produced by new streptomyces
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
AU757510C
(en)
*
|
1998-08-27 |
2003-09-11 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
GB9818732D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
US6909006B1
(en)
|
1999-08-27 |
2005-06-21 |
Spirogen Limited |
Cyclopropylindole derivatives
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
CA2558195C
(en)
|
2004-03-01 |
2012-11-06 |
Spirogen Limited |
11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
EP1723152B1
(en)
|
2004-03-09 |
2015-02-11 |
Spirogen Sàrl |
Pyrrolobenzodiazepines
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
US9242013B2
(en)
|
2010-04-15 |
2016-01-26 |
Seattle Genetics Inc. |
Targeted pyrrolobenzodiazapine conjugates
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
EP2558475A1
(en)
|
2010-04-15 |
2013-02-20 |
Spirogen Sàrl |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
KR101860174B1
(en)
|
2011-09-20 |
2018-05-21 |
메디뮨 리미티드 |
Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
|
CN110183470A
(en)
|
2011-10-14 |
2019-08-30 |
麦迪穆有限责任公司 |
Pyrrolobenzodiazepines are tall and erect
|
US9399073B2
(en)
|
2011-10-14 |
2016-07-26 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines
|
BR112014009055B1
(en)
|
2011-10-14 |
2021-12-14 |
Seattle Genetics, Inc. |
PYRROLOBENZODIAZEPINE COMPOUNDS, TARGET CONJUGATES, DRUG BINDING AND USE OF SAID CONJUGATES TO TREAT A PROLIFERATIVE DISEASE
|
CN104011018B
(en)
|
2011-10-14 |
2016-12-14 |
麦迪穆有限责任公司 |
Can be used for preparing the tall and erect synthetic method of Pyrrolobenzodiazepines and intermediate
|
US9526798B2
(en)
|
2011-10-14 |
2016-12-27 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
CN105102068B
(en)
|
2012-10-12 |
2018-06-01 |
Adc疗法责任有限公司 |
Pyrrolobenzodiazepines Zhuo-antibody conjugates
|
MX364329B
(en)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates.
|
PL2906253T3
(en)
|
2012-10-12 |
2019-02-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
CA2885315C
(en)
|
2012-10-12 |
2020-06-23 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
ES2660029T3
(en)
|
2012-10-12 |
2018-03-20 |
Medimmune Limited |
Antibody-pyrrolobenzodiazepine conjugates
|
WO2014057072A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
KR101819404B1
(en)
|
2012-10-12 |
2018-02-28 |
메디뮨 리미티드 |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
AU2013328628B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
US9950078B2
(en)
|
2013-10-11 |
2018-04-24 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN107148285B
(en)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
PL3544636T3
(en)
|
2017-02-08 |
2021-12-06 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
RS63502B1
(en)
|
2017-04-18 |
2022-09-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
CA3057748A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
US11318211B2
(en)
|
2017-06-14 |
2022-05-03 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
NZ761175A
(en)
|
2017-08-18 |
2024-07-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|